Levosulpiride
Levosulpiride is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against D(2) dopamine receptor and D(3) dopamine receptor. In addition, it is known to target D(4) dopamine receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
14 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Macular edema | D008269 | — | 1 | — | — | — | 1 | ||
Diabetic retinopathy | D003930 | EFO_0003770 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Dyspepsia | D004415 | EFO_0008533 | K30 | 1 | — | — | — | 1 | 2 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Abdominal pain | D015746 | R10.9 | — | — | — | — | 1 | 1 | |
Abdominal neoplasms | D000008 | — | — | — | — | 1 | 1 | ||
Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | 1 | ||
Healthy volunteers/patients | — | — | — | — | — | 1 | 1 | ||
Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | 1 | |
Regional blood flow | D012039 | — | — | — | — | 1 | 1 | ||
Ocular physiological phenomena | D009799 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | LEVOSULPIRIDE |
INN | levosulpiride |
Description | (S)-(-)-sulpiride is an optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively). It has a role as a dopaminergic antagonist, an antidepressant, an antiemetic and an antipsychotic agent. It is an enantiomer of a (R)-(+)-sulpiride. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CCN1CCC[C@H]1CNC(=O)c1cc(S(N)(=O)=O)ccc1OC |
Identifiers
PDB | — |
CAS-ID | 23672-07-3 |
RxCUI | — |
ChEMBL ID | CHEMBL267044 |
ChEBI ID | 64119 |
PubChem CID | 688272 |
DrugBank | DB00391 |
UNII ID | JTG7R315LK (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 328 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more